| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Pramipexole (also known as SND 919), an agonist of the Gαi-linked dopamine receptors D2, D3, and D4, is a potent dopamine agonist of the non-ergoline class. It is used to treat restless legs syndrome (RLS) and Parkinson's disease (PD). Pramipexole exhibits negligible affinity (500-10,000 nM) towards the α2-adrenergic receptor, 5-HT1A, 5-HT1B, and 5-HT1D. A partial/full agonist of the D2S, D2L, D3, and D4 receptor, pramipexole has a Ki of 3.9, 2.2, 0.5, and 5.1 nM for the D2S, D2L, D3, and D4 receptors, respectively.
| Targets |
D2 Receptor ( Ki = 3.9 nM ); D3 Receptor ( Ki = 0.5 nM ); D4 Receptor ( Ki = 1.3 nM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Animal Protocol |
Male Wistar rats weighing 250-300 g (16-18 weeks old)
0.25 mg/kg, 1 mg/kg Intraperitoneal injection |
|
| References |
|
| Molecular Formula |
C10H17N3S
|
|
|---|---|---|
| Molecular Weight |
211.33
|
|
| Exact Mass |
211.11
|
|
| Elemental Analysis |
C, 56.84; H, 8.11; N, 19.88; S, 15.17
|
|
| CAS # |
104632-26-0
|
|
| Related CAS # |
Pramipexole dihydrochloride; 104632-25-9; Dexpramipexole dihydrochloride; 104632-27-1; Pramipexole dihydrochloride hydrate; 191217-81-9; Dexpramipexole;104632-28-2; Pramipexole-d5; 1217975-28-4
|
|
| Appearance |
Solid powder
|
|
| SMILES |
CCCN[C@H]1CCC2=C(C1)SC(=N2)N
|
|
| InChi Key |
FASDKYOPVNHBLU-ZETCQYMHSA-N
|
|
| InChi Code |
InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
|
|
| Chemical Name |
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.03.00
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 10 mg/mL (47.32 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7319 mL | 23.6597 mL | 47.3194 mL | |
| 5 mM | 0.9464 mL | 4.7319 mL | 9.4639 mL | |
| 10 mM | 0.4732 mL | 2.3660 mL | 4.7319 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04759703 | Recruiting | Drug: Pramipexole Drug: Placebo |
Sleep Disorder Opioid-use Disorder |
Massachusetts General Hospital | January 24, 2022 | Phase 2 Phase 3 |
| NCT05825235 | Recruiting | Drug: Pramipexole | Anhedonia Depression |
Region Skane | April 21, 2023 | Phase 3 |
| NCT05355337 | Recruiting | Drug: Pramipexole Drug: Placebo |
Anhedonia Depression |
Region Skane | February 8, 2023 | Phase 3 |
| NCT05748600 | Recruiting | Drug: Dexpramipexole Dihydrochloride Drug: Placebo |
Eosinophilic Asthma Asthma; Eosinophilic |
Areteia Therapeutics | January 30, 2023 | Phase 3 |
| NCT05003648 | Recruiting | Drug: Pramipexole Drug: Placebo |
Adrenoleukodystrophy Restless Legs Syndrome |
Massachusetts General Hospital | April 1, 2023 | Phase 4 |
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
